{
  "symbol": "ABBV",
  "year": 2022,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2126,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.099
  },
  "top_positive": [
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 United States $ 10,348 $ 9,750 6.1 % 6.1 % International 3,190 3,260 (2.1) % 3.2 % Net revenues $ 13,538 $ 13,010 4.1 % 5.4 % 2022 Form 10-Q | 28 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 Immunology Humira United States $ 3,993 $ 3,907 2.2 % 2.2 % International 743 960 (22.6) % (17.9) % Total $ 4,736 $ 4,867 (2.7) % (1.8) % Skyrizi United States $ 781 $ 481 62.3 % 62.3 % International 159 93 71.2 % 82.9 % Total $ 940 $ 574 63.7 % 65.6 % Rinvoq United States $ 311 $ 245 26.8 % 26.8 % International 154 58 >100.0 % >100.0 % Total $ 465 $ 303 53.6 % 57.3 % Hematologic Oncology Imbruvica United States $ 874 $ 999 (12.4) % (12.4) % Collaboration revenues 299 269 11.0 % 11.0 % Total $ 1,173 $ 1,268 (7.4) % (7.4) % Venclexta United States $ 228 $ 225 1.7 % 1.7 % International 245 180 35.8 % 45.2 % Total $ 473 $ 405 16.9 % 21.1 % Aesthetics Botox Cosmetic United States $ 413 $ 305 35.5 % 35.5 % International 228 172 32.5 % 38.6 % Total $ 641 $ 477 34.4 % 36.6 % Juvederm Collection United States $ 148 $ 123 20.1 % 20.1 % International 262 198 32.2 % 37.7 % Total $ 410 $ 321 27.5 % 30.9 % Other Aesthetics United States $ 285 $ 300 (4.9) % (4.9) % International 38 43 (9.9) % (6.2) % Total $ 323 $ 343 (5.5) % (5.0) % Neuroscience Botox Therapeutic United States $ 500 $ 429 16.5 % 16.5 % International 114 103 10.7 % 17.1 % Total $ 614 $ 532 15.4 % 16.6 % Vraylar United States $ 427 $ 346 23.4 % 23.4 % Duodopa United States $ 24 $ 25 (5.6) % (5.6) % International 97 104 (6.9) % 0.5 % Total $ 121 $ 129 (6.7) % (0.8) % Ubrelvy United States $ 138 $ 81 70.0 % 70.0 % Qulipta United States $ 11 $ \u2014 n/m n/m Other Neuroscience United States $ 173 $ 156 11.0 % 11.0 % International 4 4 11.4 % 12.2 % Total $ 177 $ 160 11.0 % 11.0 % 2022 Form 10-Q | 29 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 Eye Care Lumigan/Ganfort United States $ 67 $ 66 1.5 % 1.5 % International 73 77 (5.7) % 0.7 % Total $ 140 $ 143 (2.4) % 1.0 % Alphagan/Combigan United States $ 70 $ 80 (11.5) % (11.5) % International 37 38 (3.9) % 5.5 % Total $ 107 $ 118 (9.0) % (6.0) % Restasis United States $ 235 $ 267 (11.9) % (11.9) % International 11 13 (18.1) % 1.9 % Total $ 246 $ 280 (12.2) % (11.3) % Other Eye Care United States $ 124 $ 117 5.5 % 5.5 % International 154 159 (2.4) % 4.8 % Total $ 278 $ 276 0.9 % 5.1 % Other Key Products Mavyret United States $ 169 $ 170 (1.0) % (1.0) % International 211 245 (13.9) % (7.2) % Total $ 380 $ 415 (8.6) % (4.6) % Creon United States $ 287 $ 274 4.7 % 4.7 % Linzess/Constella United States $ 233 $ 215 7.9 % 7.9 % International 7 7 6.0 % 10.2 % Total $ 240 $ 222 7.8 % 7.9 % All other $ 1,211 $ 1,476 (18.0) % (17.1) % Total net revenues $ 13,538 $ 13,010 4.1 % 5.4 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.9965
    },
    {
      "sent": "AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt.",
      "score": 0.9803
    },
    {
      "sent": "AbbVie\u2019s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.",
      "score": 0.9186
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    }
  ],
  "forward_snippets": [
    "AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace.",
    "AbbVie\u2019s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands."
  ]
}